Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients

Valle, Mario; Speeten, Kurt Van der; Garofalo, Alfredo

doi:10.1002/jso.21321

Cited by 89 publications

(53 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3, No. 2;2014 was completely disappeared in 17 (50%) of 34 patients after one session of LHIPEC. Facchiano, Risio, Kianmanesh and Msika (2012) and Valle, Van del Speeten (2009) reported the results of 57 patients who had been treated using LHIPEC, and the complete clinical regression of ascites was found in all the patients.…”

Section: Discussionmentioning

confidence: 93%

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Yonemura¹,

Canbay²,

Sako³

et al. 2014

CCO

View full text Add to dashboard Cite

Background: The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer-patients with peritoneal metastasis (PM). Materials and Methods:Thirty-five patients with PM were enrolled, and were treated with neoadjuvant laparoscopic HIPEC (LHIPEC). LHIPEC was performed at 42 to 43 centigrade for 60 minutes adding 3 liter of saline plus 12.5mg/m2 of Mitomycin C with Cisplatin (50mg/m 2 ). Second session of LHIPEC was done one month after the first LHIPEC in all cases. At the second session of LHIPEC, ascites volume, peritoneal cytology and peritoneal cancer index (PCI) were examined again.Results: Intraoperative complications of bowel injury were experienced in one and three at 1 st and 2 nd session of laparoscopy, respectively. There was no mortality after LHIPEC. Ascites was completely disappeared in 17 of 34 patients at the second session of laparoscopy. PFCCs had been detected in 28 (80.0%) patients at the 1 st session, and the positive cytology changed to be negative in 16 (57.1%) of 28 patients at the second session. PCI at the 2 nd session (12.5 ± 10.5) was significantly lower than that at the 1 st session (16.8 ± 9.6) (P=0.023). PCI levels at the 2 nd session changed to be 0 in 6 patients. Conclusion:This new method is not only a safe and convenient method for predicting feasibility of complete cytoredution, but also an effective treatment to control malignant ascites and to eradicate PFCCs before cytoreductive surgery. Furthermore, LHIPEC can reduce PCI levels.

show abstract

Section: Discussionmentioning

confidence: 93%

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Yonemura¹,

Canbay²,

Sako³

et al. 2014

CCO

View full text Add to dashboard Cite

show abstract

“…It has shown to provide treatment benefits greater than conventional methods including diuretics, repeated paracentesis and systemic chemotherapy with a complete and definitive resolution of the ascites was observed in up to 94 % of patients [53,54,55]. Some centres have also performed curative intent laparoscopic CRS/HIPEC in selected patients with limited PC.…”

Section: Perfusion Techniquesmentioning

confidence: 99%

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

Valle

Alzahrani

Sugarbaker

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combined have been recognized as standard of care for treatment of a subset of patients with peritoneal carcinomatosis (PC). The aim of CRS is to eliminate all macroscopic disease through a series of visceral resections followed by targeting any residual microscopic disease with intraperitoneal chemotherapy, exposing the peritoneal surfaces to a high concentration of chemotherapy with a lower systemic toxicity. Different regimes of intraperitoneal chemotherapy include HIPEC, early postoperative intraperitoneal chemotherapy (EPIC) and bidirectional chemotherapy. The efficacy and modality of treatment with intraperitoneal chemotherapy is dependent on multiple factors including the chosen cytotoxic agent and its pharmacokinetics and pharmacodynamics. There is no standardized methodology for intraperitoneal chemotherapy administration. This review will discuss the pharmacological principles of the various intraperitoneal chemotherapy techniques.

show abstract

“…HIPEC can have morbidity and therefore should not be used for patients with bulky residual disease [46] . Palliative use for ascites may always be considered [45,47] . Even if cytoreduction is incomplete, HIPEC is less useful for patients with high burden of peritoneal metastatic disease as measured by PCI.…”

Section: Glehen Et Almentioning

confidence: 99%

Gastric cancer: prevention and treatment of peritoneal metastases

Sugarbaker¹

2018

JCMT

View full text Add to dashboard Cite

Gastric cancer is an aggressive malignancy that may metastasize through the bloodstream to the liver, through lymphatics to regional lymph nodes, or by penetration of the peritoneal lining of the stomach to result in seeding of the abdominal and pelvis surfaces. Peritoneal metastases are the most common mode of cancer dissemination. Technologies to prevent or treat peritoneal metastases from advanced gastric cancer are presented in this manuscript. The world's literature, both recent and over the past three decades, was reviewed in order to identify publications that present information regarding gastric cancer peritoneal metastases. Over one dozen randomized controlled trials to test perioperative chemotherapy for prevention of peritoneal metastases were reviewed. All of the trials performed with regional chemotherapy during or shortly after gastrectomy were positive. The clinical data regarding the treatment of peritoneal metastases diagnosed at the time of primary cancer resection or in follow-up were reviewed. Neoadjuvant intraperitoneal and systemic chemotherapy shows that some long-term survivors occur after these treatments were combined with cytoreductive surgery and gastrectomy. Similar treatments are advocated for primary gastric cancer with cytology positive for gastric cancer but no visible implants. Surgery for gastric cancer should be combined with perioperative systemic and regional chemotherapy in order to maximally benefit patients with this disease by reducing the negative impact of peritoneal metastases on survival.

show abstract

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi‐institutional retrospective analysis in 52 patients

Cited by 89 publications

References 40 publications

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy

Gastric cancer: prevention and treatment of peritoneal metastases

Contact Info

Product

Resources

About